{
    "clinical_study": {
        "@rank": "146377", 
        "arm_group": [
            {
                "arm_group_label": "Plant-based ingredient to a starchy meal", 
                "arm_group_type": "Other", 
                "description": "Plant-based ingredient"
            }, 
            {
                "arm_group_label": "Starchy meal alone", 
                "arm_group_type": "Other", 
                "description": "No plant-based ingredient"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to determine the extent to which foods containing a plant-based\n      ingredient affect blood glucose and hormonal response in healthy subjects."
        }, 
        "brief_title": "Effect of a Plant-based Ingredient on Generalized Hormonal Responses", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males, Age at start of the study >20 and <50 years;\n\n          -  Body mass index (BMI) \u2265 20,0 and \u2264 25,0 kg/m2;\n\n          -  Apparently healthy: no medical conditions which might affect the study measurements,\n             absorption, metabolism and distribution (including diabetes type 1 and type 2,\n             gastrointestinal dysfunction, gastrointestinal surgery and inflammatory diseases);\n\n          -  Fasting blood glucose value of subjects is \u2265 3.4 and \u2264 6.1 mmol/litre (i.e. 62-110\n             mg/dl) at screening;\n\n          -  Agreeing to be informed about medically relevant personal test-results by a\n             physician;\n\n          -  Informed consent signed;\n\n          -  Willing to comply to study protocol during study;\n\n          -  Covered by Health Insurance System and/or in compliance with the recommendations of\n             National Law in force relating to biomedical research.\n\n          -  Accessible veins on arms as determined by examination at screening.\n\n        Exclusion Criteria:\n\n          -  Any history of diabetes, hyper- (or hypo-) glycemia or other disorder of glucose\n             metabolism;\n\n          -  Blood donation in the past 2 months;\n\n          -  Reported participation in another nutritional or biomedical trial 3 months before the\n             pre-study examination or during the study;\n\n          -  Reported participation in night shift work two weeks prior to pre-study investigation\n             or during the study. Night work is defined as working between midnight and 6.00 AM;\n\n          -  Reported intense sporting activities > 10h/w;\n\n          -  Consumption of > 21 alcoholic drinks in a typical week;\n\n          -  Not being used to eat breakfast;\n\n          -  Reported use of any nicotine containing products in the six months preceding the\n             study and during the study itself;\n\n          -  Use of medication which interferes with study measurements;\n\n          -  Reported dietary habits: medically prescribed diet, slimming diet;\n\n          -  Not used to eat 3 meals a day;\n\n          -  Vegetarian;\n\n          -  Reported weight loss/gain (>10%) in the last six month before the study;\n\n          -  Being an employee of Unilever and CRO;\n\n          -  Allergy or intolerance to food products and aversion to food products provided during\n             the study;\n\n          -  Subject who cannot be contacted in case of emergency;\n\n          -  Subject who, in the judgment of the investigator, is likely to be non-compliant or\n             uncooperative during the study, or unable to cooperate because of a language problem,\n             poor mental development;\n\n          -  Subject under guardianship;\n\n          -  Subject who would receive more than 4500 euro's as indemnities for his participation\n             in biomedical research within the 12 last months, including the indemnities for the\n             present study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003586", 
            "org_study_id": "FDS-NAA-1462"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Plant-based ingredient to a starchy meal", 
                    "Starchy meal alone"
                ], 
                "intervention_name": "plant-based ingredient", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Plant-based ingredient to a starchy meal", 
                    "Starchy meal alone"
                ], 
                "intervention_name": "No plant-based ingredient", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "subjects", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gieres", 
                    "country": "France"
                }, 
                "name": "Eurofins Optimed Clinical research"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of a Plant-based Ingredient on Generalized Hormonal Responses", 
        "other_outcome": {
            "description": "Effect on blood glucose response.", 
            "measure": "Blood glucose response (+iAUC)", 
            "safety_issue": "No", 
            "time_frame": "120 and 180 minutes"
        }, 
        "overall_official": {
            "affiliation": "EUROFINS OPTIMED, GIERES - France", 
            "last_name": "Yves DONAZZOLO, M.D., M.Sc.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Amylin (total) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Ghrelin (active) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Glucose-dependent insulinotropic peptide (gastric inhibitory polypeptide, GIP) (total) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Glucagon-like peptide-1 (GLP-1) (active) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Leptin will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Pancreatic polypeptide (PP) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Peptide YY (PYY) (total) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Insulin will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "C-peptide will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }, 
            {
                "description": "Glucagon will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "120 minutes"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003586"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Amylin (total) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Ghrelin (active) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Glucose-dependent insulinotropic peptide (gastric inhibitory polypeptide, GIP) (total) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Pancreatic polypeptide (PP) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Peptide YY (PYY) (total) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Leptin will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Glucagon will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Insulin will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "C-peptide will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }, 
            {
                "description": "Glucagon-like peptide-1 (GLP-1) (active) will be assessed.", 
                "measure": "AUC of post-prandial hormones", 
                "safety_issue": "No", 
                "time_frame": "180 and 240 minutes"
            }
        ], 
        "source": "Unilever R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Unilever R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}